BioInvent International AB
STO:BINV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (36), the stock would be worth kr-145.86 (765% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -5.4 | kr21.95 |
0%
|
| Industry Average | 36 | kr-145.86 |
-765%
|
| Country Average | 21.3 | kr-86.29 |
-493%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
B
|
BioInvent International AB
STO:BINV
|
1.4B SEK | -5.4 | -4.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -2 855 158.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
373.6B USD | 23.4 | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.6B USD | 21.9 | 23 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.4B USD | 24.2 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -480.6 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.6B USD | 33.9 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.7B USD | 19.9 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 159.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD | 35.5 | 29.5 |
Market Distribution
| Min | 0.6 |
| 30th Percentile | 12.2 |
| Median | 21.3 |
| 70th Percentile | 31.9 |
| Max | 19 008.8 |
Other Multiples
BioInvent International AB
Glance View
BioInvent International AB engages in the research and development of novel and immuno-modulatory antibodies for the treatment of cancer. The company is headquartered in Lund, Skane and currently employs 84 full-time employees. The company went IPO on 2001-06-12. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The firm has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
